Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8301MR)

This product GTTS-WQ8301MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8301MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10852MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ13738MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ7861MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ1547MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13838MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ4087MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ10526MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ2742MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-139
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW